30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Integra LifeSciences

4Q13 orthopaedic revenue: $82.7MM, +5%

  • Extremities +13% (U.S. +16%)
  • Orthopaedics +7%
  • U.S. Spine & Other -3%


  • Extremities led by hardware growth +20% (citing controlled market release of Titan shoulder lines); U.S. foot/ankle up in mid-teens
  • Upper and lower hardware increased in double-digits
  • Private label spine decreased in low-double digits, primarily due to decline in sales with one large partner, discontinuation of certain products
  • Small decline in U.S. spine hardware offset by mid-teens increase in orthobiologics (DBM)


2013 orthopaedic revenue: $314.6MM, +0.4%

  • U.S. Extremities $134.6MM, +10%
  • U.S. Spine & Other $179.9MM, -6%


  • Global spine hardware +2%; “not as successful” in launching to larger developing countries (like China) vs. Europe
  • Private label spine ~$59MM, expected to decline >$10MM during 2014
  • Launched several new spine products at year-end 2013, to transition to full launch in 2014, including NanoMetalene interbody and Laminoplasty devices
  • 2014 launches include expandable interbody device; refreshed wrist, foot/ankle products; full launch of Titan shoulder already in progress (monthly case volume has more than doubled since its launch)
  • Investing in reps and training for conversion to shoulder line